229 related articles for article (PubMed ID: 32451408)
21. Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.
Qian G; Jiang N; Wang D; Newman S; Kim S; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Chen ZG; Saba NF
Cancer; 2015 Oct; 121(20):3600-11. PubMed ID: 26195293
[TBL] [Abstract][Full Text] [Related]
22. Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma.
Chi LH; Chang WM; Chang YC; Chan YC; Tai CC; Leung KW; Chen CL; Wu AT; Lai TC; Li YJ; Hsiao M
Sci Rep; 2017 Aug; 7(1):9031. PubMed ID: 28831179
[TBL] [Abstract][Full Text] [Related]
23. A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Radhakrishnan A; Nanjappa V; Raja R; Sathe G; Puttamallesh VN; Jain AP; Pinto SM; Balaji SA; Chavan S; Sahasrabuddhe NA; Mathur PP; Kumar MM; Prasad TS; Santosh V; Sukumar G; Califano JA; Rangarajan A; Sidransky D; Pandey A; Gowda H; Chatterjee A
Sci Rep; 2016 Oct; 6():36132. PubMed ID: 27796319
[TBL] [Abstract][Full Text] [Related]
24. Targeting of EZH2 inhibits epithelial‑mesenchymal transition in head and neck squamous cell carcinoma via regulating the STAT3/VEGFR2 axis.
Zhao M; Hu X; Xu Y; Wu C; Chen J; Ren Y; Kong L; Sun S; Zhang L; Jin R; Zhou X
Int J Oncol; 2019 Nov; 55(5):1165-1175. PubMed ID: 31545422
[TBL] [Abstract][Full Text] [Related]
25. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
Xie J; Li Q; Ding X; Gao Y
Cell Physiol Biochem; 2018; 46(2):676-686. PubMed ID: 29621758
[TBL] [Abstract][Full Text] [Related]
26. Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC.
Zhang K; Jones L; Lim S; Maher CA; Adkins D; Lewis J; Kimple RJ; Fertig EJ; Chung CH; Van Tine BA; Ellis MJ; Herrlich A; Michel LS
Oncotarget; 2014 Oct; 5(19):9281-94. PubMed ID: 25238142
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition.
Ban MJ; Byeon HK; Yang YJ; An S; Kim JW; Kim JH; Kim DH; Yang J; Kee H; Koh YW
Cancer Sci; 2018 Dec; 109(12):3816-3825. PubMed ID: 30343534
[TBL] [Abstract][Full Text] [Related]
28. The effects of GLUT1 on the survival of head and neck squamous cell carcinoma.
Li S; Yang X; Wang P; Ran X
Cell Physiol Biochem; 2013; 32(3):624-34. PubMed ID: 24022001
[TBL] [Abstract][Full Text] [Related]
29. Inflammatory mediators drive metastasis and drug resistance in head and neck squamous cell carcinoma.
St John MA
Laryngoscope; 2015 Mar; 125 Suppl 3():S1-11. PubMed ID: 25646683
[TBL] [Abstract][Full Text] [Related]
30. CD100-plexin-B1 induces epithelial-mesenchymal transition of head and neck squamous cell carcinoma and promotes metastasis.
Zhang C; Qiao H; Guo W; Liu Y; Yang L; Liu Y; Jin B; Fu M; Wang G; Li W
Cancer Lett; 2019 Jul; 455():1-13. PubMed ID: 30981760
[TBL] [Abstract][Full Text] [Related]
31. Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.
Duvvuri U; George J; Kim S; Alvarado D; Neumeister VM; Chenna A; Gedrich R; Hawthorne T; LaVallee T; Grandis JR; Bauman JE
Clin Cancer Res; 2019 Oct; 25(19):5752-5758. PubMed ID: 31308059
[TBL] [Abstract][Full Text] [Related]
32. Adenosine receptor 2B activity promotes autonomous growth, migration as well as vascularization of head and neck squamous cell carcinoma cells.
Wilkat M; Bast H; Drees R; Dünser J; Mahr A; Azoitei N; Marienfeld R; Frank F; Brhel M; Ushmorov A; Greve J; Goldberg-Bockhorn E; Theodoraki MN; Doescher J; Laban S; Schuler PJ; Hoffmann TK; Brunner C
Int J Cancer; 2020 Jul; 147(1):202-217. PubMed ID: 31846065
[TBL] [Abstract][Full Text] [Related]
33. The Special AT-rich Sequence Binding Protein 1 (SATB1) and its role in solid tumors.
Frömberg A; Engeland K; Aigner A
Cancer Lett; 2018 Mar; 417():96-111. PubMed ID: 29306014
[TBL] [Abstract][Full Text] [Related]
34. Intracellular reduction in ATP levels contributes to CYT997-induced suppression of metastasis of head and neck squamous carcinoma.
Zhao X; Lang L; He L; Gao L; Chyan D; Xiong Y; Li H; Peng H; Teng Y
J Cell Mol Med; 2019 Feb; 23(2):1174-1182. PubMed ID: 30450674
[TBL] [Abstract][Full Text] [Related]
35. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
[TBL] [Abstract][Full Text] [Related]
36. Anti-cancer effects of disulfiram in head and neck squamous cell carcinoma via autophagic cell death.
Park YM; Go YY; Shin SH; Cho JG; Woo JS; Song JJ
PLoS One; 2018; 13(9):e0203069. PubMed ID: 30212479
[TBL] [Abstract][Full Text] [Related]
37. Pairing a prognostic target with potential therapeutic strategy for head and neck cancer.
Lek SM; Li K; Tan QX; Shannon NB; Ng WH; Hendrikson J; Tan JWS; Lim HJ; Chen Y; Koh KKN; Skanthakumar T; Kwang XL; Chong FT; Leong HS; Tay G; Putri NE; Lim TKH; Hwang JSG; Ang MK; Tan DSW; Tan NC; Tan HK; Kon OL; Soo KC; Iyer NG; Ong CJ
Oral Oncol; 2020 Dec; 111():105035. PubMed ID: 33091845
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic Role of ZFAS1 lncRNA in Head and Neck Squamous Cell Carcinomas.
Kolenda T; Guglas K; Kopczyńska M; Teresiak A; Bliźniak R; Mackiewicz A; Lamperska K; Mackiewicz J
Cells; 2019 Apr; 8(4):. PubMed ID: 31010087
[TBL] [Abstract][Full Text] [Related]
39. Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation.
Gannon OM; Merida de Long L; Endo-Munoz L; Hazar-Rethinam M; Saunders NA
Clin Cancer Res; 2013 Jan; 19(2):428-41. PubMed ID: 23186778
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of SATB1 by shRNA suppresses the proliferation of cutaneous malignant melanoma.
Zhang L; Cheng F; He R; Chen H; Liu Y; Sun J
Cancer Biother Radiopharm; 2014 Mar; 29(2):77-82. PubMed ID: 24392879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
